Invited Talks
Kathryn Mittauer, PhD
AAPM Annual Meeting (with B. Thomadsen, J. Palta, J. Dobbins, D. Pavord, and B. Fraass), “New Member Symposium–New Initiatives for AAPM,” 2018
AAPM Annual Meeting 2018.“ViewRay MRIdian: From Cobalt-60 to Linear Accelerator,” ViewRay booth presentation, 2018
AAPM, North Central Chapter, “MR-guided Radiotherapy: from Cobalt-60 to Linear Accelerator,” 2018
Sun Nuclear’s Quality Assurance and Dosimetry Symposium, “Implementation of a MR-guided Online Adaptive Radiotherapy Program,” SAM session, 2018
Winter Institute of Medical Physics (WIMP), “MR-guided Online Adaptive Radiotherapy,” 2018
AAPM Annual Meeting “Clinical Experiences with Online Adaptive Radiotherapy,” ViewRay booth presentation, 2017
Ravi Patel, MD, PhD
University of Southern California Cancer Center Grand Rounds, “Utilization of Low-Dose Radiation to Enhance the Efficacy of Cancer Immunotherapy and Enhance Abscopal Responses,” 2019
University of Wisconsin Cancer Biology Seminar Series, “Combination Radiation and Immunotherapy: Where We Are Now and Future Directions,” 2018
ASTRO Annual Meeting, Moderator. Session: Biology 2 – “Radiation and Immune Response Session I,” 2018
Parkview Medical Center, Department of Medicine, “SBRT for Early Stage Lung Cancer,” 2018
Webinars
Kathryn Mittauer, PhD
“Treating Tumors that Move: The Promise and Practice of Real-time MR Image Guidance During Radiation Beam Delivery,” (with J. Ng), Imaging and Technology News (ITN), 2018
“Implementation of a MR-guided Online Adaptive Radiotherapy Program,” Best of Sun Nuclear’s Quality Assurance and Dosimetry Symposium, 2018
“MR-guidance in Radiation Therapy,” WePassed, 2018.
Oral Presentations/Presented Posters
Ravi Patel, MD, PhD
“A SITC-sponsored randomized clinical trial to determine criteria to guide clinicians on when to stopimmunotherapy through a community-driven data repository, leveraging the SITC community” Society of Immunotherapy in Cancer. Washington DC, Nov. 2018 – Poster Presentation – Late Breaking Abstract
“Molecular targeted radiotherapy (MTRT) enhances the efficacy of immunotherapy increasing complete response rates of both local and distant disease in a “cold” tumor model.” Society of Immunotherapy in Cancer. Washington DC, Nov. 2018 – Poster Presentation
“A novel molecularly targeted radiotherapeutic agent (MTRT) to deliver immunomodulatory radiation to multiple pediatric and adult solid tumors.” Radiological Society of North America, Chicago, IL, Nov 2018 – Oral Presentation